• 1
    Cvitkovic E; International Nasopharynx Cancer Study Group. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (≥N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int J Radiat Oncol Biol Phys. 1996; 35: 463-469.
  • 2
    Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998; 16: 1310-1317.
  • 3
    Lin JC, Jan JS, Hsu CY, et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003; 21: 631-637.
  • 4
    Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 2005; 23: 6730-6738.
  • 5
    Zhang L, Zhao C, Peng PJ, et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol. 2005; 23: 8461-8468.
  • 6
    Chen Y, Liu MZ, Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of China. Int J Radiat Oncol Biol Phys. 2008; 71: 1356-1364.
  • 7
    Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant decetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009; 27: 242-249.
  • 8
    Lee AW, Tung SY, Chua DT, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced. J Natl Cancer Inst. 2010; 102: 1188-1198.
  • 9
    Lee AW, Tung SY, Chan ATC, et al. A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. Radiother Oncol. 2011; 98: 15-22.
  • 10
    Chua DT, Ma J, Sham JS, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of 2 phase III trials. J Clin Oncol. 2005; 23: 1118-1124.
  • 11
    Chan ATC, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2005; 97: 536-539.
  • 12
    Chang YS, Tyan YS, Liu ST, et al. Detection of Epstein-Barr virus DNA sequences in nasopharyngeal carcinoma cells by enzymatic DNA amplification. J Clin Microbiol. 1990; 28: 2398-2402.
  • 13
    Chen CL, Wen WN, Chen JY, et al. Detection of Epstein-Barr virus genome in nasopharyngeal carcinoma by in situ DNA hybridization. Intervirology. 1993; 36: 91-98.
  • 14
    Lee WY, Hsiao JR, Jin YT, et al. Epstein-Barr virus detection in neck metastases by in-situ hybridization in fine-needle aspiration cytologic studies: an aid for differentiating the primary site. Head Neck. 2000; 22: 336-240.
  • 15
    Tsai ST, Jin YT, Su IJ. Expression of EBER1 in primary and metastatic nasopharyngeal carcinoma tissues using in situ hybridization. A correlation with WHO histologic subtypes. Cancer. 1996; 77: 231-236.
  • 16
    Macdonald MR, Freeman JL, Hui MF, et al. Role of Epstein-Barr virus in fine-needle aspirates of metastatic neck nodes in the diagnosis of nasopharyngeal carcinoma. Head Neck. 1995; 17: 487-493.
  • 17
    Chao TY, Chow KC, Chang JY, et al. Expression of Epstein-Barr virus-encoded RNAs as a marker for metastatic undifferentiated nasopharyngeal carcinoma. Cancer. 1996; 78: 24-29.
  • 18
    Lo YM, Chan LY, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999; 59: 1188-1191.
  • 19
    Lo YM, Chan LY, Chan ATC, et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res. 1999; 59: 5452-5455.
  • 20
    Lo YM, Chan ATC, Chan LY, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res. 2000; 60: 6878-6881.
  • 21
    Chan ATC, Lo YM, Zee B, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst. 2002; 94: 1614-1619.
  • 22
    Leung SF, Chan ATC, Zee B, et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of post-therapy distant failure in patients with early stage nasopharyngeal carcinoma of undifferentiated type. Cancer. 2003; 98: 288-291.
  • 23
    Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol. 2006; 24: 5414-5418.
  • 24
    Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004; 350: 2461-2470.
  • 25
    Lin JC, Wang WY, Liang WM, et al. Long-term prognostic effects of plasma Epstein-Barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2007; 68: 1342-1348.
  • 26
    Hou X, Zhao Chong, Guo Y, et al. Different clinical significance of pre- and post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy. Clin Oncol. 2011; 23: 128-133.
  • 27
    Le QT, Jones CD, Yau TK, et al. A comparison study of different PCR assays in measuring circulating plasma Epstein-Barr virus DNA levels in patients with nasopharyngeal carcinoma. Clin Cancer Res. 2005; 11: 5700-5707.
  • 28
    Lo YMD, Leung SF, Chan LYS, et al. Plasma cell-free Epstein-Barr virus DNA quantitation in patients with nasopharyngeal carcinoma. Correlation with clinical staging. Ann NY Acad Sci. 2000; 906: 99-101.
  • 29
    Sozzi G, Roz L, Conte D, et al. Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. J Natl Cancer Inst. 2005; 97: 1848-1850.
  • 30
    Chan ATC, Ngan RKC, Hui EP, et al. A multicenter randomized controlled trial of adjuvant chemotherapy in nasopharyngeal carcinoma with residual plasma EBV DNA following primary radiotherapy or chemoradiotherapy [abstract]. J Clin Oncol. 2012; 30(suppl). Abstract 5511.